Brief: AN2 Therapeutics Provides Update On Ebo-301 Phase 2/3 Study Evaluating Epetraborole For Treatment-Refractory Mycobacterium Avium Complex (Mac) Lung Disease

AN2 Therapeutics

08/08/2024 23:33

Aug 8 (Reuters) - AN2 Therapeutics Inc  ANTX.O :
    * AN2 THERAPEUTICS PROVIDES UPDATE ON EBO-301 PHASE 2/3
STUDY
EVALUATING EPETRABOROLE FOR TREATMENT-REFRACTORY MYCOBACTERIUM
AVIUM COMPLEX (MAC) LUNG DISEASE
    * AN2 THERAPEUTICS - RESTRUCTURING AND COST SAVINGS
ASSOCIATED
WITH DISCONTINUATION OF EBO-301 STUDY EXPECTED TO EXTEND CASH
RUNWAY THROUGH 2027
    * AN2 THERAPEUTICS INC: PLANS TO SHIFT FOCUS TO INTERNAL
BORON
CHEMISTRY PLATFORM AND ONGOING PIPELINE PROGRAMS
    * AN2 THERAPEUTICS- EBO-301 STUDY TO DISCONTINUED POST
TOPLINE
RESULTS FROM PHASE 2 PART OF STUDY IN TREATMENT-REFRACTORY
PATIENTS WITH MAC LUNG DISEASE

Source text for Eikon:  ID:nBw5bR6Kva 
Further company coverage:  ANTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))